Literature DB >> 35480987

Nanodelivery of nucleic acids.

Bárbara B Mendes1,2,3, João Conniot1,2,3, Aviram Avital4,5,3, Dongbao Yao6,3, Xingya Jiang7,3, Xiang Zhou6,3, Noga Sharf-Pauker4,5,3, Yuling Xiao7,3, Omer Adir4,5,3, Haojun Liang6, Jinjun Shi7, Avi Schroeder4, João Conde1,2.   

Abstract

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented opportunity to overcome these drawbacks; owing to their tunability with diverse physico-chemical properties, they can readily be functionalized with any type of biomolecules/moieties for selective targeting. Nucleic acid therapeutics such as antisense DNA, mRNA, small interfering RNA (siRNA) or microRNA (miRNA) have been widely explored to modulate DNA or RNA expression Strikingly, gene therapies combined with nanoscale delivery systems have broadened the therapeutic and biomedical applications of these molecules, such as bioanalysis, gene silencing, protein replacement and vaccines. Here, we overview how to design smart nucleic acid delivery methods, which provide functionality and efficacy in the layout of molecular diagnostics and therapeutic systems. It is crucial to outline some of the general design considerations of nucleic acid delivery nanoparticles, their extraordinary properties and the structure-function relationships of these nanomaterials with biological systems and diseased cells and tissues.

Entities:  

Year:  2022        PMID: 35480987      PMCID: PMC9038125          DOI: 10.1038/s43586-022-00104-y

Source DB:  PubMed          Journal:  Nat Rev Methods Primers        ISSN: 2662-8449


  212 in total

Review 1.  Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond).

Authors:  Ulrich Lächelt; Ernst Wagner
Journal:  Chem Rev       Date:  2015-04-15       Impact factor: 60.622

Review 2.  Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9.

Authors:  Hong-Xia Zhang; Ying Zhang; Hao Yin
Journal:  Mol Ther       Date:  2019-01-25       Impact factor: 11.454

Review 3.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

4.  Systemic delivery of factor IX messenger RNA for protein replacement therapy.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Kiyoshi Tachikawa; Pattraranee Limphong; Jerel B Vega; Priya P Karmali; Pad Chivukula; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-15       Impact factor: 11.205

5.  Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model.

Authors:  João Conde; Nuria Oliva; Yi Zhang; Natalie Artzi
Journal:  Nat Mater       Date:  2016-07-25       Impact factor: 43.841

Review 6.  Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.

Authors:  Kunn Hadinoto; Ajitha Sundaresan; Wean Sin Cheow
Journal:  Eur J Pharm Biopharm       Date:  2013-07-17       Impact factor: 5.571

7.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

8.  Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting.

Authors:  Qin Dai; Carl Walkey; Warren C W Chan
Journal:  Angew Chem Int Ed Engl       Date:  2014-04-02       Impact factor: 15.336

Review 9.  Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.

Authors:  Yating Sun; Yarong Zhao; Xiuting Zhao; Robert J Lee; Lesheng Teng; Chenguang Zhou
Journal:  Molecules       Date:  2017-10-13       Impact factor: 4.411

10.  Towards vaccine equity: Should big pharma waive intellectual property rights for COVID-19 vaccines?

Authors:  Melody Okereke
Journal:  Public Health Pract (Oxf)       Date:  2021-07-30
View more
  3 in total

Review 1.  Application of mRNA Technology in Cancer Therapeutics.

Authors:  Yesim Eralp
Journal:  Vaccines (Basel)       Date:  2022-08-05

Review 2.  Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy.

Authors:  Aiswarya Chaudhuri; Dulla Naveen Kumar; Rasheed A Shaik; Basma G Eid; Ashraf B Abdel-Naim; Shadab Md; Aftab Ahmad; Ashish Kumar Agrawal
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

3.  Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Authors:  Sahar Eljack; Stephanie David; Areeg Faggad; Igor Chourpa; Emilie Allard-Vannier
Journal:  Int J Pharm X       Date:  2022-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.